PlantPharm BioMed’s platform technology has been proven by more than 30 years of R&D, field testing and human clinical trials, demonstrating that biopharmaceuticals can be multiplied in plants and delivered successfully to the human body in Oral Solid Dose form.

As a result of this research, PlantPharm grew the world’s first lot of Hepatitis B vaccine in genetically stable, vaccine-bearing plants, that proved to be equivalent to standard Hepatitis B vaccines in an FDA authorized, double-blind, human clinical trial.

Our Mission is to be a partner to traditional pharmaceutical companies, allowing them to penetrate markets that are currently out of reach, and to provide a more robust and sustainable healthcare system worldwide, through the development and manufacturing of plant-grown biopharmaceuticals.
Close-up rendering of a DNA strand
USDA APHIS Award

A pelletized COVID-19 vaccine for wild and farmed animals

In December 2023, PlantPharm BioMed was awarded more than $900,000 from the U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) to develop a stable, feed-delivered SARS-CoV-2 (COVID-19) animal vaccine. This work is part of the global One Health Initiative, which addresses the role animals play in the zoonotic transfer of disease to humans.

A herd of white-tailed deer grazing in a field
Future applications

Expanding the platform

PlantPharm is looking to expand its platform application to any number of human or animal biopharmaceutical products. PlantPharm will look to partner with major pharmaceutical companies to transform the production of their existing vaccines, monoclonal antibodies, proteins or peptides, into low-cost, plant-based systems.

Read the technology overview →
[ADOBE STOCK: healthy potato plants in a research field, high resolution]
Company

Delavan, Wisconsin

Incorporated 2008

PlantPharm BioMed is headquartered in Delavan, Wisconsin, with its office, production lab, and pilot plant located in southeastern Wisconsin.